Merck-SpringWorks deal received US antitrust clearance
MLex Summary: The US waiting period for Merck's acquisition of SpringWorks Therapeutics for $3.9 billion has expired, SpringWorks said in a filing with the US Securities and Exchange Commission.Extract. ...To view the full article, register now.
Already a subscriber? Click here to view full article